ClinicalTrials.gg
CompletedNCT04982575Updated Dec 23, 2025Results posted

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

A Phase 2 interventional study of Semaglutide 2.4 mg and Cagrilintide 2.4 mg in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.

Enrollment
13th of 15
92 · median 274
Started
2021
the only one that year
Phase 2
4 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
15 of 15
Novo Nordisk A/S

Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment, is the only one that started in 2021, is one of 4 in phase 2, and was the 1st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone.

Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective.

Participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by chance.

A dummy medicine (placebo) looks like the study medicine but does not contain any active medicine. The dummy medicine is in the study to see if the study medicine works as expected.

Participants will get 2 injections per week on the same day. Participants will take the study medicine with a pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show how.

The study will last for about 39 weeks. Participants will have 12 visits at the clinic and 5 phone calls with the study doctor.

At 6 of the clinic visits participants must not eat and drink for 8 hours before the visit (water is allowed).

Women who can become pregnant cannot take part in this study. Only women that are surgically sterilised or post-menopausal are allowed to participate in this study Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female of non- or male
  • Age above or equal to 18 years at the time of signing
  • (BMI) greater than or equal to 27.0 kg/m\^2
  • Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening
  • (HbA1c) of 7.5-10.0% (58-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening
  • Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at maximum tolerated or effective dose as judged by the investigator: metformin with or without Sodium-glucose co-transporter-2 (SGLT2) inhibitor

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 days and prior insulin treatment for gestational diabetes are allowed
  • Renal impairment with estimated (eGFR) below 60 ml/min/1.73m\^2 by central laboratory at screening
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Cagrilintide 2.4 mg and semaglutide 2.4 mg

    Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.

    Drug: Semaglutide 2.4 mg · Drug: Cagrilintide 2.4 mg

  • Active comparator
    Cagrilintide 2.4 mg and placebo (semaglutide)

    Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks

    Drug: Cagrilintide 2.4 mg · Drug: Placebo (semaglutide)

  • Active comparator
    Semaglutide 2.4 mg and Placebo (cagrilintide)

    Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks

    Drug: Semaglutide 2.4 mg · Drug: Placebo (cagrilintide)

Interventions

  • Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks

  • Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks

  • DrugPlacebo (semaglutide)

    Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks

  • DrugPlacebo (cagrilintide)

    Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)

    Change in HbA1c from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site. The on-treatment without rescue medication period is a subset of the 'on-treatment' observation period and represents the time period where subjects are considered exposed to trial product but have not initiated any rescue medications.

    Time frame: Week 0, Week 32

Secondary outcomes

  1. Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)

    Change in HbA1c from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

    Time frame: Week 0, Week 32

  2. Percentage Change in Body Weight: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)

    Percenatge change in body weight from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

    Time frame: Week 0, Week 32

  3. Change in Body Weight (Kilogram): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)

    Change in body weight from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

    Time frame: Week 0, Week 32

  4. Change in Fasting Plasma Glucose (FPG): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)

    Change in FPG from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

    Time frame: Week 0, Week 32

  5. CGM: Change in Mean Glucose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)

    Change in mean glucose from baslline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

    Time frame: Week 0, Week 32

  6. Percentage of Time Above Range (TAR) Greater Than 10.0 mmol/L (Greater Than 180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)

    Percentage of TAR greater than 10.0 mmol/L (greater than 180 mg/dL) at week 32 is presented. The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range greater than 10.0 mmol/L (greater than 180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

    Time frame: At week 32

  7. Percentage of Time in Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)

    Percentage of TIR 3.9-10.0 mmol/L (70-180 mg/dL) at week 32 is presented. The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

    Time frame: At week 32

  8. Number of Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical trial participants administered or using a medicinal product, whether or not considered related to the medicinal product or usage. A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. On treatment observation period starts at the date of first dose of trial product and ends at the first date of any of the following; the date of last dose of trial product +35 days for AEs and hypoglycaemic episodes/+ 14 days for other endpoints; the end-date for the 'in-trial' observation period.

    Time frame: From baseline (week 0) to week 37

  9. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG) meter or severe hypoglycaemic episodes (level 3) that occurred from week 0 to week 37 are presented. On treatment observation period starts at the date of first dose of trial product and ends at the first date of any of the following; the date of last dose of trial product +35 days for AEs and hypoglycaemic episodes/+ 14 days for other endpoints; the end-date for the 'in-trial' observation period.

    Time frame: From baseline (week 0) to week 37

07

Results

Posted Jul 27, 2023

Participant flow

The trial was conducted at 17 sites in the United States.

Participant flow — Overall Study
MilestoneCagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)Semaglutide 2.4 mg + Placebo (Cagrilintide)
Started313031
Completed293029
Not completed202
Withdrew: Withdrawal by subject202

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)

Change in HbA1c from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site. The on-treatment without rescue medication period is a subset of the 'on-treatment' observation period and represents the time period where subjects are considered exposed to trial product but have not initiated any rescue medications.

Time frame:
Week 0, Week 32
Reported as:
Mean · Percentage of HbA1c
Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
Percentage of HbA1cCagrilintide 2.4 mg + Semaglutide 2.4 mgSemaglutide 2.4 mg + Placebo (Cagrilintide)
Change from Baseline - in-trial-2.2 ± 0.9-1.9 ± 1.0
Change from Baseline - on treatment without rescue-2.2 ± 0.9-2.0 ± 1.0
Statistical analysis
  • Cagrilintide 2.4 mg + Semaglutide 2.4 mg vs Semaglutide 2.4 mg + Placebo (Cagrilintide) · Mixed Models Analysis · p = 0.2284 · Treatment difference: -0.30 · 95% CI -0.79 to 0.19
SecondaryChange in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)

Change in HbA1c from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

Time frame:
Week 0, Week 32
Reported as:
Mean · Percentage point of HbA1c
Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)
Percentage point of HbA1cCagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)
Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)-2.2 ± 0.9-0.8 ± 0.9
SecondaryPercentage Change in Body Weight: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)

Percenatge change in body weight from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

Time frame:
Week 0, Week 32
Reported as:
Mean · Percentage of body weight
Percentage Change in Body Weight: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
Percentage of body weightCagrilintide 2.4 mg + Semaglutide 2.4 mgSemaglutide 2.4 mg + Placebo (Cagrilintide)
Percentage Change in Body Weight: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)-14.7 ± 9.3-5.0 ± 4.0
SecondaryChange in Body Weight (Kilogram): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)

Change in body weight from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

Time frame:
Week 0, Week 32
Reported as:
Mean · Kilogram
Change in Body Weight (Kilogram): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
KilogramCagrilintide 2.4 mg + Semaglutide 2.4 mgSemaglutide 2.4 mg + Placebo (Cagrilintide)
Change in Body Weight (Kilogram): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)-15.4 ± 10.1-5.3 ± 4.2
SecondaryChange in Fasting Plasma Glucose (FPG): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)

Change in FPG from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

Time frame:
Week 0, Week 32
Reported as:
Mean · Millimoles per liter (mmol/L)
Change in Fasting Plasma Glucose (FPG): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
Millimoles per liter (mmol/L)Cagrilintide 2.4 mg + Semaglutide 2.4 mgSemaglutide 2.4 mg + Placebo (Cagrilintide)
Change in Fasting Plasma Glucose (FPG): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)-3.4 ± 3.1-2.7 ± 2.3
SecondaryCGM: Change in Mean Glucose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)

Change in mean glucose from baslline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

Time frame:
Week 0, Week 32
Reported as:
Mean · Millimoles per liter (mmol/l)
CGM: Change in Mean Glucose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)
Millimoles per liter (mmol/l)Cagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)
CGM: Change in Mean Glucose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)-3.5 ± 2.3-1.0 ± 2.2
SecondaryPercentage of Time Above Range (TAR) Greater Than 10.0 mmol/L (Greater Than 180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)

Percentage of TAR greater than 10.0 mmol/L (greater than 180 mg/dL) at week 32 is presented. The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range greater than 10.0 mmol/L (greater than 180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

Time frame:
At week 32
Reported as:
Mean · Percentage of time
Percentage of Time Above Range (TAR) Greater Than 10.0 mmol/L (Greater Than 180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)
Percentage of timeCagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)
Percentage of Time Above Range (TAR) Greater Than 10.0 mmol/L (Greater Than 180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)10.3 ± 15.730.9 ± 25.2
SecondaryPercentage of Time in Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)

Percentage of TIR 3.9-10.0 mmol/L (70-180 mg/dL) at week 32 is presented. The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.

Time frame:
At week 32
Reported as:
Mean · Percentage of time
Percentage of Time in Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)
Percentage of timeCagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)
Percentage of Time in Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)88.9 ± 15.368.9 ± 25.1
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical trial participants administered or using a medicinal product, whether or not considered related to the medicinal product or usage. A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. On treatment observation period starts at the date of first dose of trial product and ends at the first date of any of the following; the date of last dose of trial product +35 days for AEs and hypoglycaemic episodes/+ 14 days for other endpoints; the end-date for the 'in-trial' observation period.

Time frame:
From baseline (week 0) to week 37
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsCagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)Semaglutide 2.4 mg + Placebo (Cagrilintide)
Number of Treatment Emergent Adverse Events (TEAEs)212422
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG) meter or severe hypoglycaemic episodes (level 3) that occurred from week 0 to week 37 are presented. On treatment observation period starts at the date of first dose of trial product and ends at the first date of any of the following; the date of last dose of trial product +35 days for AEs and hypoglycaemic episodes/+ 14 days for other endpoints; the end-date for the 'in-trial' observation period.

Time frame:
From baseline (week 0) to week 37
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
EpisodesCagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)Semaglutide 2.4 mg + Placebo (Cagrilintide)
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)000

Adverse events

Collected over From baseline (week 0) to week 37. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cagrilintide 2.4 mg + Semaglutide 2.4 mg0/31 (0%)0/31 (0%)18/31 (58.1%)
Cagrilintide 2.4 mg + Placebo (Semaglutide)0/30 (0%)4/30 (13.3%)18/30 (60%)
Semaglutide 2.4 mg + Placebo (Cagrilintide)0/31 (0%)2/31 (6.5%)18/31 (58.1%)
Most frequent serious events
Most frequent serious events
EventCagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)Semaglutide 2.4 mg + Placebo (Cagrilintide)
Acute myocardial infarctionCardiac disorders0/311/300/31
Chest painGeneral disorders0/311/300/31
Coronary artery diseaseCardiac disorders0/311/300/31
Deep vein thrombosisVascular disorders0/311/300/31
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/311/300/31
HypotensionVascular disorders0/310/301/31
Loss of consciousnessNervous system disorders0/310/301/31
Most frequent other events
Showing 10 of 28
Most frequent other events
EventCagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)Semaglutide 2.4 mg + Placebo (Cagrilintide)
NauseaGastrointestinal disorders9/314/305/31
COVID-19Infections and infestations5/315/303/31
ConstipationGastrointestinal disorders5/314/304/31
DiarrhoeaGastrointestinal disorders5/312/302/31
HeadacheNervous system disorders0/313/303/31
ConjunctivitisInfections and infestations0/310/303/31
FatigueGeneral disorders3/311/300/31
GastroenteritisInfections and infestations2/311/303/31
Gastrooesophageal reflux diseaseGastrointestinal disorders3/311/300/31
Upper respiratory tract infectionInfections and infestations2/312/303/31

Baseline characteristics

Full analyis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(Years)Cagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)Semaglutide 2.4 mg + Placebo (Cagrilintide)Total
Mean56 ± 1062 ± 757 ± 1058 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Cagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)Semaglutide 2.4 mg + Placebo (Cagrilintide)Total
Female1371333
Male18231859
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)Semaglutide 2.4 mg + Placebo (Cagrilintide)Total
Hispanic or Latino1061329
Not Hispanic or Latino21241863
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cagrilintide 2.4 mg + Semaglutide 2.4 mgCagrilintide 2.4 mg + Placebo (Semaglutide)Semaglutide 2.4 mg + Placebo (Cagrilintide)Total
American Indian or Alaska Native0000
Asian0314
Native Hawaiian or Other Pacific Islander0011
Black or African American55515
White26222472
More than one race0000
Unknown or Not Reported0000
08

Study locations

23 sites
  • Uni of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Valley Research
    Fresno, California 93720, United States
  • Pacific Clinical Studies
    Los Alamitos, California 90720, United States
  • Velocity Clin Res Los Angeles
    Los Angeles, California 90017, United States
  • Encompass Clinical Research_Spring Valley
    Spring Valley, California 91978, United States
  • New West Physicians,Inc.
    Golden, Colorado 80401, United States
  • FPA Clinical Research
    Kissimmee, Florida 34741, United States
  • Florida Inst For Clin Res
    Orlando, Florida 32825, United States
  • Clinical Trial Res Assoc,Inc
    Plantation, Florida 33324, United States
  • Ellipsis Group
    Alpharetta, Georgia 30022, United States
  • East West Med Res Inst
    Honolulu, Hawaii 96814, United States
  • Macoupin Research Group
    Gillespie, Illinois 62033, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Plains Clinical Research Center, LLC_Fargo
    Fargo, North Dakota 58104, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • DCOL Ctr for Clin Res
    Longview, Texas 75605, United States
  • Selma Medical Associates
    Winchester, Virginia 22601-3834, United States
  • Capital Clin Res Ctr,LLC
    Olympia, Washington 98502, United States
09

References and documents

Publications

  • Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023 Aug 26;402(10403):720-730. doi: 10.1016/S0140-6736(23)01163-7. Epub 2023 Jun 23. PubMed 37364590 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jul 2022, 11 months.

Results were first posted in Jul 2023, 1 year after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2021
First posted
Jul 29, 2021
StartActual
Aug 2, 2021
Primary completionActual
Jul 7, 2022
CompletionActual
Jul 7, 2022
Results first posted
Jul 27, 2023
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04982575
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 29, 2021
Start date
Aug 2, 2021
Primary completion
Jul 7, 2022
Completion
Jul 7, 2022
Results posted
Jul 27, 2023
Last update
Dec 23, 2025

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion